Eastern Canadian Colorectal Cancer Consensus Conference 2017

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2018 Aug 17

PMID 30111967

Citations 4

Authors

S F McGee

W AlGhareeb

C H Ahmad

D Armstrong

S Babak

S Berry

J Biagi

C Booth

D Bosse

P Champion

B Colwell

N Finn

R Goel

S Gray

J Green

M Harb

A Hyde

A Jeyakumar

D Jonker

S Kanagaratnam

P Kavan

A Macmillan

A Muinuddin

N Patil

G Porter

E Powell

R Ramjeesingh

M Raza

S Rorke

M Seal

F Servidio-Italiano

J Siddiqui

J Simms

L Smithson

S Snow

E St-Hilaire

T Stuckless

A Tate

M Tehfe

M Thirlwell

E Tsvetkova

M Valdes

M Vickers

K Virik

S Welch

C Marginean

T Asmis

Affiliations

Soon will be listed here.

Abstract

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John's, Newfoundland and Labrador, 28-30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including ■ identification and management of hereditary gastric and colorectal cancer (crc);■ palliative systemic therapy for metastatic gastric cancer;■ optimum duration of preoperative radiation in rectal cancer-that is, short- compared with long-course radiation;■ management options for peritoneal carcinomatosis in crc;■ implications of tumour location for treatment and prognosis in crc; and■ new molecular markers in crc.

Citing Articles

Assessing neoadjuvant therapy recommendations in 19 national and international guidelines for rectal cancer.

Mroczkowski P, Atay S, Viebahn R Tech Coloproctol. 2024; 28(1):94.

PMID: 39102159 PMC: 11300497. DOI: 10.1007/s10151-024-02969-5.

Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with Wild-Type Left-Sided Tumours in Canada.

Boyne D, Ngan E, Carbonell C, Wani R, Cirone Morris C, Martinez D Curr Oncol. 2023; 30(9):8220-8232.

PMID: 37754511 PMC: 10528146. DOI: 10.3390/curroncol30090596.

Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada.

Samawi H, Brezden-Masley C, Afzal A, Cheung W, Dolley A Curr Oncol. 2019; 26(5):319-329.

PMID: 31708650 PMC: 6821111. DOI: 10.3747/co.26.5107.

Advances in Identification of Susceptibility Gene Defects of Hereditary Colorectal Cancer.

Liu Q, Tan Y J Cancer. 2019; 10(3):643-653.

PMID: 30719162 PMC: 6360424. DOI: 10.7150/jca.28542.

References

Lynch H, de la Chapelle A . Hereditary colorectal cancer. N Engl J Med. 2003; 348(10):919-32. DOI: 10.1056/NEJMra012242. View

Arnold D, Lueza B, Douillard J, Peeters M, Lenz H, Venook A . Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017; 28(8):1713-1729. PMC: 6246616. DOI: 10.1093/annonc/mdx175. View

Witkamp A, Bree E, Kaag M, Boot H, Beijnen J, van Slooten G . Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001; 37(8):979-84. DOI: 10.1016/s0959-8049(01)00058-2. View

Ngan S, Burmeister B, Fisher R, Solomon M, Goldstein D, Joseph D . Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012; 30(31):3827-33. DOI: 10.1200/JCO.2012.42.9597. View

Overman M, McDermott R, Leach J, Lonardi S, Lenz H, Morse M . Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18(9):1182-1191. PMC: 6207072. DOI: 10.1016/S1470-2045(17)30422-9. View

Shen P, Hawksworth J, Lovato J, Loggie B, Geisinger K, Fleming R . Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004; 11(2):178-86. DOI: 10.1245/aso.2004.05.009. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Elias D, Gilly F, Boutitie F, Quenet F, Bereder J, Mansvelt B . Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2009; 28(1):63-8. DOI: 10.1200/JCO.2009.23.9285. View

Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

10.

Holch J, Ricard I, Stintzing S, Modest D, Heinemann V . The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer. 2016; 70:87-98. DOI: 10.1016/j.ejca.2016.10.007. View

11.

Venook A, Niedzwiecki D, Lenz H, Innocenti F, Fruth B, Meyerhardt J . Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017; 317(23):2392-2401. PMC: 5545896. DOI: 10.1001/jama.2017.7105. View

12.

Wu Z, Li Z, Ji J . Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in advanced gastric cancer. Transl Gastroenterol Hepatol. 2017; 1:63. PMC: 5244745. DOI: 10.21037/tgh.2016.07.03. View

13.

van der Post R, Vogelaar I, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N . Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015; 52(6):361-74. PMC: 4453626. DOI: 10.1136/jmedgenet-2015-103094. View

14.

Gonzalez-Pons M, Cruz-Correa M . Colorectal Cancer Biomarkers: Where Are We Now?. Biomed Res Int. 2015; 2015:149014. PMC: 4461726. DOI: 10.1155/2015/149014. View

15.

Thuss-Patience P, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K . Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011; 47(15):2306-14. DOI: 10.1016/j.ejca.2011.06.002. View

16.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

17.

Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T . Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG.... J Clin Oncol. 2013; 31(35):4438-44. DOI: 10.1200/JCO.2012.48.5805. View

18.

Jones J, Renfro L, Al-Shamsi H, Schrock A, Rankin A, Zhang B . BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017; 35(23):2624-2630. PMC: 5549454. DOI: 10.1200/JCO.2016.71.4394. View

19.

Sieber O, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips R . Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med. 2003; 348(9):791-9. DOI: 10.1056/NEJMoa025283. View

20.

Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S . FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1065-75. DOI: 10.1016/S1470-2045(14)70330-4. View